Articles tagged with Type 2 Diabetes
Researchers discover telomere shortening as a predictor of coronary heart disease in pre-diabetics and Type 2 diabetics. Early indication of telomeres starting to shorten may indicate the onset of diabetes and ultimately predict CAD.
Researchers found that periodontal disease can cause pre-diabetic characteristics and contribute to the progression of Type 2 diabetes. The study used rat models to investigate the relationship between periodontitis and pre-diabetes, highlighting the importance of oral health in preventing diabetes.
A study by Duke University Medical Center found that having both type 2 diabetes and depression significantly increases the risk of death for heart patients. This is because individuals with diabetes who also experience depression may be less motivated to follow their self-care regimen, thereby putting them at a higher risk.
Researchers identified genetic and cellular mechanisms that enable mice with high-fat diets to resist obesity and diabetes, suggesting a role for brown fat cells. The study may lead to new therapies for obesity and prevention of type 2 diabetes.
Researchers mapped genetic makeup of type-2 diabetes in unprecedented detail, identifying four loci that correspond to a 70% genetic background risk. The study also reveals a mutation in the zinc transporter SLC30A8, potentially leading to new treatments for insulin deficiency.
A recent study published in Diabetes Technology and Therapeutics demonstrated that Diachrome safely improves blood glucose levels and cholesterol metabolism in people with type 2 diabetes. The 30-day study showed a significantly greater reduction in glucose levels, suggesting potential benefits for improved blood sugar control.
A new study aims to improve diabetes management by linking patients' glucose levels to their pharmacists. Half of the participants will share their data with their pharmacist for lifestyle advice, while the other half will manage it themselves.
A new study found a genetic link between the 'diabetes gene' (calpain-10) and polycystic ovary syndrome (PCOS), which affects up to five percent of females. The study suggests that specific variants of the CAPN10 gene may contribute to PCOS susceptibility, providing hope for diagnosis and treatment.
A new clinical trial, CHICAGO, demonstrated that pioglitazone (ACTOS) reduced the progression of carotid intima-media thickness (CIMT), a surrogate marker for heart attack and stroke, by 0.013 mm. The study also showed improved glycemic control, decreased triglycerides, and increased HDL-C levels with ACTOS treatment.
A study at the University of Illinois Chicago found that pioglitazone significantly slowed the thickening of carotid artery walls, reducing the risk of heart attack. The medication was shown to be effective regardless of age, sex, or diabetes duration.
A Finnish study found that intensive lifestyle interventions can sustainably reduce the risk of developing type 2 diabetes. After four years, participants showed a 36% reduction in relative risk, attributed to achieving weight loss and increased physical activity.
The proportion of people with type 2 diabetes in Asia has increased rapidly, with younger age groups developing the condition and suffering longer from chronic complications. The region's healthcare systems are under threat as a result.
A new study published in the Journal of Periodontology found that periodontal therapy decreases lipid peroxide levels in diabetic patients, reducing oxidative stress. This reduction is comparable to that seen in nondiabetic patients, suggesting a potential benefit for patients with Type 2 diabetes.
Rimonabant reduces bodyweight and improves blood glucose control in patients with type 2 diabetes. The study suggests that rimonabant could be used as a new treatment option for patients who have not responded to standard treatments.
A major national study found that about 154,000 of 80.7 million children and adolescents nationwide had diabetes in 2001. Non-Hispanic white children had the highest diabetes rate, with type 1 diabetes being the most common form.
Researchers found that increasing leptin production in the hypothalamus helps regulate insulin secretion, keeping blood glucose levels normal. Gene therapy successfully reversed type 2 diabetes in diabetic mice, even after a high-fat diet.
A study at the University of Chicago Medical Center found that short or poor quality sleep is associated with reduced control of blood-sugar levels in African Americans with diabetes. The research suggests that improving sleep duration and quality may be an inexpensive way to improve health outcomes for patients with type 2 diabetes.
A new study suggests that taking rosiglitazone, a medication for type 2 diabetes, can prevent the disease in people at high risk. The three-year trial found that this combination reduced the risk by about two-thirds, preventing around 144 cases of diabetes per 1000 people.
The partnership aims to address pediatric health concerns through groundbreaking scientific research and monitoring disease, with the goal of finding long-term solutions for childhood obesity and type 2 diabetes. The collaboration will also support increased awareness and education on these critical health issues.
ACTOS demonstrated significant improvements in reducing the risk of heart attacks, strokes, and cardiovascular death in high-risk patients with type 2 diabetes. The study showed a 23% reduction in heart attacks and an 18% reduction in combined risk of cardiovascular death, nonfatal heart attack, or nonfatal stroke.
Researchers at Washington University School of Medicine successfully transplanted pig pancreatic primordia into rats with type 2 diabetes, curing the condition without the need for immune suppression drugs. The approach, similar to one that cured type 1 diabetes in previous studies, uses embryonic cells to produce insulin.
New analyses of the PROactive Study found that ACTOS (pioglitazone HCl) significantly reduced the risk of recurrent stroke in high-risk patients with type 2 diabetes, with a 47% reduction in incidence and a 28% decrease in combined risk of death, MI, or stroke.
Researchers have identified two chemical compounds, PBA and TUDCA, that alleviate ER stress and restore normal glucose homeostasis in type 2 diabetic mice. These compounds also improved insulin response, reduced fatty liver disease, and prevented JNK activation, offering a potential new approach to treating metabolic syndrome.
A low-fat vegan diet has been shown to treat type 2 diabetes more effectively than a standard diabetes diet, with significant improvements in blood sugar control and weight loss. The diet also appears to have favorable effects on cholesterol levels and kidney function.
A study found that youth-onset type 2 diabetes is associated with a substantially increased risk of end-stage kidney disease and death between 25-55 years old. Participants with early-onset diabetes had a significantly higher incidence rate of kidney disease compared to those with older-onset diabetes.
A study found that a gene variant increases the risk of developing type 2 diabetes, but adopting healthy lifestyle changes significantly reduces this genetic risk. The research, conducted by the DPP Genetics subgroup, identified a single nucleotide polymorphism in the TCF7L2 gene as a key risk factor for the disease.
A 20-year study found that type 2 diabetes is associated with primary open angle glaucoma (POAG), a leading cause of blindness. Researchers observed over 76,000 women and found a positive association between type 2 diabetes and POAG, regardless of duration.
A study of 28,812 postmenopausal women found that daily decaffeinated coffee consumption was associated with a 33% lower risk of developing type 2 diabetes. The risk reduction was independent of factors such as weight and physical activity.
A study of 28,812 postmenopausal women found that those who drank more than six cups of coffee per day had a 22% reduced risk of type 2 diabetes, while decaf drinkers saw a 33% decrease. Other minerals and nutrients in coffee may contribute to its beneficial effects.
Researchers are investigating how type 2 diabetes affects brain function and memory. The Edinburgh Type 2 Diabetes Study aims to identify risk factors linked to altered brain function in people with diabetes, which could inform the cause of diabetes-related memory problems.
A study found that offspring of type 2 diabetic parents exhibit endothelial dysfunction and increased risk of atherosclerosis, even without diabetes. The research suggests that early treatment may prevent progression of the disease, highlighting the importance of identifying high-risk groups.
Researchers found that elevated RBP4 levels are closely associated with insulin resistance, metabolic syndrome, and increased risk of developing type 2 diabetes. Exercise therapy can lower RBP4 levels and improve insulin sensitivity in individuals at risk of diabetes.
The CHICAGO trial will examine ACTOS' effect on blood vessel health and atherosclerosis, beyond glycemic control. The 18-month study aims to gather further information about the management of cardiovascular disease in people with type 2 diabetes.
Researchers found that Gardenia extract contains the chemical genipin, which blocks UCP2 enzyme and improves insulin secretion. In both animals and humans, high concentrations of UCP2 appear to inhibit insulin secretion from the pancreas and increase the risk of type 2 diabetes.
A study by Joslin researchers found that the PKC-beta enzyme is responsible for fluid retention and weight gain associated with popular type 2 diabetes drugs. The study suggests a potential treatment using PKC-beta inhibitors to prevent these side effects.
A nationwide survey shows a significant gap in understanding of type 2 diabetes management, with patients feeling knowledgeable about their condition but not following treatment regimens as prescribed. The Diabetes Roundtable advocates for a team-centered approach involving patients, physicians, and educators to improve care outcomes.
A team of Canadian and American researchers has identified the role of SHP-1 in regulating blood glucose levels and insulin sensitivity. The study used genetically modified mice to demonstrate that SHP-1 inhibition can improve glucose metabolism at the liver and muscle levels, potentially leading to new treatments for type 2 diabetes.
Pre-diabetes and undiagnosed type 2 diabetes affect millions, increasing heart disease risk. Research shows nearly 22% of people aged 65+ have diabetes, with significant disparities among ethnic groups.
A national survey found that approximately 134,071 US adolescents have type 2 diabetes, with 39,005 having the condition and 2,769,736 having impaired fasting glucose levels. The study suggests a significant public health concern among this age group due to the high conversion rate from impaired glucose tolerance to type 2 diabetes.
The Netherlands Organization for Scientific Research has developed medical jargon reduction methods, enabling hospital departments to evaluate the quality of terminology systems. By using standardized terms, data can be more easily accessed and used for improving patient care and epidemiological research.
A new study finds that PCOS is associated with elevated cholesterol levels, insulin resistance, and metabolic syndrome in mothers. The long-term health consequences of PCOS are significant, and mothers should be screened for cardiovascular disease risk factors.
Individuals with type 2 diabetes have a heightened risk of developing uric-acid stones, likely due to their highly acidic urine. The study suggests that factors associated with type 2 diabetes or insulin resistance account for the increased acidity.
Researchers at Joslin Diabetes Center discovered a link between Necdin and E2F4 proteins, altered after patients took the drug rosiglitazone. The study suggests that thiazolidinediones work by altering cell differentiation states, offering new potential targets for diabetes treatment.
Researchers found that timely diagnosis of diabetes improves blood pressure control, glucose management, and overall health outcomes. Studies also suggest that reengineering primary care practice through practice redesign may be necessary to substantially improve chronic illness care.
Women who implemented intensive lifestyle changes and lost 5-7% of their weight had fewer episodes of weekly incontinence compared to those in the metformin or placebo groups. Weight loss was particularly effective in reducing stress incontinence, which is linked to obesity and diabetes.
The NIH supports expansive basic and clinical research portfolios on obesity and type 2 diabetes, including genetic studies, nuclear receptors, and lifestyle interventions. Epidemiological studies provide insights into risk factors and inform future clinical endeavors.
A three-week diet and exercise study shows that Type 2 diabetes and metabolic syndrome can be reversed through lifestyle changes, with half of participants experiencing a clinical diagnosis reversal. The regimen improved factors contributing to heart disease, such as insulin resistance and high cholesterol.
A high-fat diet suppresses the activity of GnT-4a glycosyltransferase, leading to impaired insulin secretion and type 2 diabetes. The study suggests that people with an inherited predisposition to type 2 diabetes may have variations in the gene for GnT-4a.
A single gene encoding the enzyme GnT-4a is key to enabling pancreatic beta cells to sense blood glucose levels and produce insulin. In mice fed a high-fat diet, this enzyme's suppression led to type 2 diabetes.
A study found that exposure to persistent organochlorine pollutants like CB-153 and DDE is significantly associated with a high prevalence of type 2 diabetes among fishermen and their wives. The results show that those with higher blood levels of these pollutants have a higher risk of developing the disease.
A study of 83,585 and 73,418 women found that longer breastfeeding durations were associated with a reduced risk of type 2 diabetes, with risks decreasing by 15% and 14% per additional year of lactation. The findings suggest that maternal lactation may play a role in reducing the risk of type 2 diabetes in young and middle-aged women.
The PROactive study shows ACTOS significantly reduced the recurrence of heart attacks and acute coronary syndrome in high-risk patients with type 2 diabetes. The medication demonstrated a 28 percent reduction in fatal or non-fatal heart attacks, as well as a 37 percent risk reduction in acute coronary syndrome.
A study of 14,200 patients with type 2 diabetes found that fenofibrate reduced total CVD events by 11% due to a decrease in non-fatal heart attacks and bypass surgery. The drug was well-tolerated but associated with increased risks of pancreatitis and pulmonary embolism.
Research reveals that offspring of type 2 diabetic parents have reduced mitochondrial content and impaired muscle glucose uptake, increasing their risk of developing insulin resistance and type 2 diabetes. Reduced mitochondrial function can lead to lipid accumulation in muscle cells, further exacerbating the condition.
Researchers found African-American men had significantly lower calcified plaque in coronary and carotid arteries. The study, which included 1,000 white participants and 180 black participants, used high-speed CT scans to measure plaque levels.
Scientists have identified genetic variants in PPARG and CAPN10 genes that increase the risk of developing Type 2 diabetes, particularly in individuals with other risk factors. A large-scale study found that these variants can predict diabetes in high-risk individuals from families with T2D.
Patients with diabetes and depression are more likely to have cardiovascular and cerebrovascular complications, as well as increased mortality rates. The study found that a sedentary lifestyle was an important independent predictor of mortality from diabetes.
A study published in The Lancet found that pioglitazone reduces the risk of cardiovascular events in patients with type 2 diabetes. The treatment group experienced fewer adverse events and a lower risk of death from heart failure compared to the placebo group.
The BIDMC research team is studying the hormones and brain pathways regulating body weight and glucose metabolism, with a goal of advancing diabetes treatment and prevention. Jointly funded by the Smith Family Foundation and the American Diabetes Association, this award supports scientists conducting research on type 2 diabetes.
Results from two Phase II studies support the efficacy profile of sitagliptin, a novel DPP-IV inhibitor, improving glycaemic control in patients with type 2 diabetes. Treatment with sitagliptin resulted in no significant weight gain and a low risk of hypoglycaemia.